Biotechnology fuels growth of new meds and vaccines

Share this article:

Three hundred and twenty-four new medicines and vaccines developed through biotechnology are now being tested to treat nearly 150 diseases, according to a new survey of biotechnology medicines released by the Pharmaceutical Research
and Manufacturers of America (PhRMA). All of the new biotechnology
medicines and vaccines are now in clinical trails or awaiting approval from the FDA. The survey found that the new biotechnology medicines include 154 medicines to treat cancer, 43 to treat
infectious disease, 26 to treat autoimmune disorders, 16 to treat neurological disorders and 17 to treat HIV/AIDS and related-conditions.
"The biotechnology medicine revolution is giving patients and doctors
new hope and new tools to fight disease," said Alan Holmer, PhRMA
president and chief executive.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.